197 related articles for article (PubMed ID: 34365943)
1. Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer.
Lu X
Curr Med Chem; 2022; 29(11):1851-1865. PubMed ID: 34365943
[TBL] [Abstract][Full Text] [Related]
2. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
3. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer.
Mohsenzadegan M; Bavandpour P; Nowroozi MR; Amini E; Kourosh-Arami M; Momeni SA; Bokaie S; Sharifi L
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2131-2146. PubMed ID: 33745426
[TBL] [Abstract][Full Text] [Related]
4. Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy.
Cao Y; Li Q; Liu H; He X; Huang F; Wang Y
Cancer Biomark; 2021; 32(2):237-248. PubMed ID: 34092621
[TBL] [Abstract][Full Text] [Related]
5. Tim-3 finds its place in the cancer immunotherapy landscape.
Acharya N; Sabatos-Peyton C; Anderson AC
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601081
[TBL] [Abstract][Full Text] [Related]
6. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy.
Yang R; Hung MC
Sci China Life Sci; 2017 Oct; 60(10):1058-1064. PubMed ID: 29027155
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3).
Rietz TA; Teuscher KB; Mills JJ; Gogliotti RD; Lepovitz LT; Scaggs WR; Yoshida K; Luong K; Lee T; Fesik SW
J Med Chem; 2021 Oct; 64(19):14757-14772. PubMed ID: 34597046
[TBL] [Abstract][Full Text] [Related]
8. The role of TIM-3 in sepsis: a promising target for immunotherapy?
Wang C; Liu J; Wu Q; Wang Z; Hu B; Bo L
Front Immunol; 2024; 15():1328667. PubMed ID: 38576606
[TBL] [Abstract][Full Text] [Related]
9. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
10. T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases.
Chen H; Zha J; Tang R; Chen G
Int Immunopharmacol; 2023 Aug; 121():110418. PubMed ID: 37290326
[TBL] [Abstract][Full Text] [Related]
11. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Ma S; Tian Y; Peng J; Chen C; Peng X; Zhao F; Li Z; Li M; Zhao F; Sheng X; Zong R; Li Y; Zhang J; Yu M; Zhu Q; Tian X; Li Y; Neckenig MR; Liu H; Zhan P; Yue X; Wu Z; Gao L; Liang X; Liu X; Li C; Ma C
Sci Transl Med; 2023 Nov; 15(722):eadg6752. PubMed ID: 37967204
[TBL] [Abstract][Full Text] [Related]
12. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Du W; Yang M; Turner A; Xu C; Ferris RL; Huang J; Kane LP; Lu B
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28300768
[TBL] [Abstract][Full Text] [Related]
13. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Th1 T Cell Differentiation by Iron
Pfeifhofer-Obermair C; Tymoszuk P; Nairz M; Schroll A; Klais G; Demetz E; Engl S; Brigo N; Weiss G
Front Immunol; 2021; 12():637809. PubMed ID: 34108960
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Sauer N; Janicka N; Szlasa W; Skinderowicz B; Kołodzińska K; Dwernicka W; Oślizło M; Kulbacka J; Novickij V; Karłowicz-Bodalska K
Cancer Immunol Immunother; 2023 Nov; 72(11):3405-3425. PubMed ID: 37567938
[TBL] [Abstract][Full Text] [Related]
16. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential.
Saleh R; Toor SM; Elkord E
Expert Opin Ther Targets; 2020 Dec; 24(12):1251-1262. PubMed ID: 33103506
[TBL] [Abstract][Full Text] [Related]
17. TIM-3: An update on immunotherapy.
Zhao L; Cheng S; Fan L; Zhang B; Xu S
Int Immunopharmacol; 2021 Oct; 99():107933. PubMed ID: 34224993
[TBL] [Abstract][Full Text] [Related]
18. TIM-3 pathway dysregulation and targeting in cancer.
Zeidan AM; Komrokji RS; Brunner AM
Expert Rev Anticancer Ther; 2021 May; 21(5):523-534. PubMed ID: 33334180
[TBL] [Abstract][Full Text] [Related]
19. Evidence for carbohydrate recognition and homotypic and heterotypic binding by the TIM family.
Wilker PR; Sedy JR; Grigura V; Murphy TL; Murphy KM
Int Immunol; 2007 Jun; 19(6):763-73. PubMed ID: 17513880
[TBL] [Abstract][Full Text] [Related]
20. Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment.
Kim HS; Chang CY; Yoon HJ; Kim KS; Koh HS; Kim SS; Lee SJ; Kane LP; Park EJ
Cancer Res; 2020 May; 80(9):1833-1845. PubMed ID: 32094297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
